Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 12/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 11/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13627499 | 0.93 | HSP90AA1 (0.46) | HSP90AA1HSP90AB1DRD2DRD3 | |
| SCHEMBL13627478 | 0.88 | HSP90AA1 (0.47) | HSP90AA1HSP90AB1 | |
| SCHEMBL13627468 | 0.87 | HSP90AA1 (0.63) | HSP90AA1HSP90AB1OPRL1 | |
| SCHEMBL13627504 | 0.86 | HSP90AA1 (0.67) | HSP90AA1HSP90AB1DRD2DRD3 | |
| SCHEMBL13627466 | 0.85 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1DRD2DRD3 | |
| SCHEMBL13627477 | 0.85 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1DRD2DRD3 | |
| SCHEMBL13627491 | 0.84 | HSP90AA1 (0.65) | HSP90AA1HSP90AB1DRD2DRD3 | |
| SCHEMBL13627517 | 0.84 | HSP90AA1 (0.53) | HSP90AA1HSP90AB1 | |
| SCHEMBL13627473 | 0.84 | HSP90AA1 (0.46) | HSP90AA1HSP90AB1 | |
| SCHEMBL13627483 | 0.84 | HSP90AA1 (0.53) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612201-B2 | Pyrazole compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-7612201-B2 | Pyrazole compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-7612201-B2 | Pyrazole compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-20060148817-A1 | Pyrazole compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| EP-1572664-A1 | PYRAZOLE COMPOUNDS | Vernalis (Cambridge) Limited (GB) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004056782-A1 | PYRAZOLE COMPOUNDS | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148817-A1 | Pyrazole compounds | NRAS, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 2/4885DRD2 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.